Consolidated revenue from operations of the company, however, rose to Rs 1,596.05 crore for the quarter under consideration as against Rs 1,453.92 crore for the same period year ago, it said.
"We have started FY 18 on a steady note, with our pharma segment recording its highest ever revenues during the quarter despite margin contraction in the US generics business", Jubilant Life Sciences Chairman Shyam S Bhartia and Co- Chairman & MD Hari S Bhartia said on the results.
The company continues to focus on operating cash generation to reduce its debt levels and strengthen the balance sheet, they added.
Shares of Jubilant Life Sciences today closed at Rs 703.70 on BSE, down 1.17 per cent from previous close.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)